Neumora Therapeutics (NMRA) Interest & Investment Income (2022 - 2026)

Neumora Therapeutics' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 59.95% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $6.1 million (down 63.56% YoY), while the FY2025 annual figure was $8.3 million, down 58.14% from the prior year.
• Interest & Investment Income was $1.2 million for Q1 2026 at Neumora Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.4 million in Q1 2024 to a low of $1.2 million in Q1 2026.
• Historically, Interest & Investment Income has averaged $3.3 million across 5 years, with a median of $3.6 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income jumped 172.97% in 2023, then slumped 67.34% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $2.3 million in 2022, then surged by 147.09% to $5.6 million in 2023, then declined by 27.59% to $4.1 million in 2024, then plunged by 67.34% to $1.3 million in 2025, then slipped by 7.79% to $1.2 million in 2026.
• The last three Interest & Investment Income figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.